Radient Technologies Inc banner

Radient Technologies Inc
XTSX:RTI

Watchlist Manager
Radient Technologies Inc Logo
Radient Technologies Inc
XTSX:RTI
Watchlist
Price: 0.005 CAD
Market Cap: CA$2.7m

P/OCF

10.8
Current
No historical data
Comparison unavailable

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
10.8
=
Market Cap
CA$2.7m
/
Operating Cash Flow
CA$250.2k

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
10.8
=
Market Cap
CA$2.7m
/
Operating Cash Flow
CA$250.2k

Valuation Scenarios

Radient Technologies Inc is trading above its 3-year average

If P/OCF returns to its 3-Year Average (10.8), the stock would be worth CA$0.01 (0% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-4%
Maximum Upside
+1%
Average Downside
1%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 10.8 CA$0.01
0%
3-Year Average 10.8 CA$0.01
0%
5-Year Average 10.8 CA$0.01
0%
Industry Average 10.4 CA$0
-4%
Country Average 10.9 CA$0.01
+1%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
CA
Radient Technologies Inc
XTSX:RTI
2.7m CAD 10.8 -0.2
US
Eli Lilly and Co
NYSE:LLY
870.6B USD 51.4 41.9
US
Johnson & Johnson
NYSE:JNJ
544.4B USD 22.6 26.4
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.2 19.3
UK
AstraZeneca PLC
LSE:AZN
225.4B GBP 20.4 29.1
CH
Novartis AG
SIX:NOVN
221.8B CHF 14.6 20
US
Merck & Co Inc
NYSE:MRK
279.4B USD 17.2 15.5
IE
Endo International PLC
LSE:0Y5F
244.4B USD 907.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 9.2 10.7
US
Pfizer Inc
NYSE:PFE
152.4B USD 12.8 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
118.4B USD 8.4 16.8
P/E Multiple
Earnings Growth PEG
CA
Radient Technologies Inc
XTSX:RTI
Average P/E: 22.1
Negative Multiple: -0.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41.9
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.4
8%
3.3
CH
Roche Holding AG
SIX:ROG
19.3
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.1
25%
1.2
CH
Novartis AG
SIX:NOVN
20
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.5
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1.1

Market Distribution

In line with most companies in Canada
Percentile
49th
Based on 1 917 companies
49th percentile
10.8
Low
0.1 — 7.2
Typical Range
7.2 — 17
High
17 —
Distribution Statistics
Canada
Min 0.1
30th Percentile 7.2
Median 10.9
70th Percentile 17
Max 26 053.9

Radient Technologies Inc
Glance View

Market Cap
2.7m CAD
Industry
Pharmaceuticals

Radient Technologies, Inc. engages in manufacture of natural ingredients in the food and beverage, nutrition and supplements, pharmaceuticals, and active care industries. The company is headquartered in Edmonton, Alberta. The company went IPO on 2011-08-24. The firm's principal activities are research, development and commercialization of technology for the extraction, isolation and purification of soluble products from a range of materials using microwave technology. The firm is focused on the formulation, manufacturing and launching of cannabis products. The company develops specialty products that contains a range of cannabinoid and terpene profiles. The company also operates a scientific and product testing laboratory that offers solutions to the cannabis and wellness spaces. Its extraction platform extracts cannabinoids from cannabis and hemp biomass. Its cannabis formulations include tinctures, topicals, sub-lingual sprays, standardized oils, stable water soluble and water dispersible powders and solid powders. Its cannabinoid-based ingredients are formulated for use in food and beverage products, personal care products and others.

RTI Intrinsic Value
Not Available
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett